2035 related articles for article (PubMed ID: 16691069)
21. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy.
Solmone M; Girardi E; Lalle E; Abbate I; D'Arminio Monforte A; Cozzi-Lepri A; Alessandrini A; Piscopo R; Ebo F; Cosco L; Antonucci G; Ippolito G; Capobianchi MR; ;
Antivir Ther; 2006; 11(1):87-94. PubMed ID: 16518964
[TBL] [Abstract][Full Text] [Related]
22. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection.
Cooper CL; Mills E; Angel JB
AIDS; 2007 Jan; 21(1):71-6. PubMed ID: 17148970
[TBL] [Abstract][Full Text] [Related]
23. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
24. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
[TBL] [Abstract][Full Text] [Related]
25. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
26. Influence of viral hepatitis on HIV infection.
Rockstroh JK
J Hepatol; 2006; 44(1 Suppl):S25-7. PubMed ID: 16338020
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events.
Stebbing J; Waters L; Mandalia S; Bower M; Nelson M; Gazzard B
Clin Infect Dis; 2005 Sep; 41(6):906-11. PubMed ID: 16107994
[TBL] [Abstract][Full Text] [Related]
28. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
29. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
[TBL] [Abstract][Full Text] [Related]
31. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
d'Arminio Monforte A; Cozzi-Lepri A; Castagna A; Antinori A; De Luca A; Mussini C; Caputo SL; Arlotti M; Magnani G; Pellizzer G; Maggiolo F; Puoti M;
Clin Infect Dis; 2009 Aug; 49(4):612-22. PubMed ID: 19591597
[TBL] [Abstract][Full Text] [Related]
32. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; Morsica G; Pizzaferri P; Ladisa N; Sighinolfi L; Chiodera A; Solmone M; Lalle E; Ippolito G; Monforte Ad; ;
Antivir Ther; 2005; 10(1):109-17. PubMed ID: 15751768
[TBL] [Abstract][Full Text] [Related]
33. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
34. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
[TBL] [Abstract][Full Text] [Related]
35. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
[TBL] [Abstract][Full Text] [Related]
36. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
Bani-Sadr F; Goderel I; Morand P; Payan C; Lunel F; Pol S; Perronne C; Carrat F; Cacoub P
AIDS; 2007 Jul; 21(12):1645-8. PubMed ID: 17630563
[TBL] [Abstract][Full Text] [Related]
37. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
38. Chronic hepatitis B and other correlates of spontaneous clearance of hepatitis C virus among HIV-infected people with hemophilia.
Melendez-Morales L; Konkle BA; Preiss L; Zhang M; Mathew P; Eyster ME; Goedert JJ
AIDS; 2007 Jul; 21(12):1631-6. PubMed ID: 17630559
[TBL] [Abstract][Full Text] [Related]
39. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
